UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): October 31, 2023 |
EVOKE PHARMA, INC.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | 001-36075 | 20-8447886 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | | | |
420 Stevens Avenue, Suite 370 | |
Solana Beach, California | | 92075 |
(Address of Principal Executive Offices) | | (Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 858 345-1494 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class
| | Trading
Symbol(s) | |
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share | | EVOK | | The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On October 30, 2023, Evoke Pharma, Inc. (the “Company") announced a summary of real-world data on the positive impact of GIMOTI (nasal metoclopramide) usage in reducing healthcare costs for patients suffering from diabetic gastroparesis (DGP) versus patients taking oral metoclopramide. The full abstract entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs for Treating Diabetic Gastroparesis Patients,” was selected and presented as for a plenary session at the American College of Gastroenterology (ACG) 2023 Annual Meeting in Vancouver, Canada.
Among many conclusions, over the 6-month post index period, Gimoti patients/payers spent approximately $15,000 less than oral metoclopramide patients/payers between medical facility and pharmacy visits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | | EVOKE PHARMA, INC. |
| | | |
Date: | November 1, 2023 | By: | /s/ Matthew J. D'Onofrio |
| | | Name: Matthew J. D'Onofrio
Title: President, Chief Operating Officer and Secretary |
